Abstract:Abstract Liver cancer is the second leading cause of cancer-related death in China and worldwide, where hepatocellular carcinoma (HCC) represents the major histological type. Previous studies have demonstrated that surveillance program combining serum marker AFP and ultrasound could greatly reduce liver cancer mortality. However, it is widely recognized that AFP has lower sensitivity for early stage of the disease and the specificity is also sub-optimal, limiting its application for early detection and timely intervention. Tumor-originated circulating cell-free DNA (ctDNA), harboring cancer-related genetic and epigenetic changes, provides new opportunity for non-invasive detection of liver cancer. In this study, we have performed parallel genetic and epigenetic profiling of cfDNA from Chinese hepatocellular carcinoma patients as well as healthy individuals by targeted bisulfite sequencing and by targeted ultra-deep sequencing. For methylome profiling, we first identified HCC-specific differentially methylated regions (DMRs) and then employed machine learning approaches to build diagnostic models to classify the plasma of HCC patients from that of healthy individuals. The training cohort consists of 148 hepatocellular carcinoma cases (median age of 63) and 84 healthy individuals (median age of 60). A random forest classifier achieved an AUC of 0.94±0.04 with 10-fold cross-validation using a panel of 21 DMR markers. Meanwhile, cfDNA mutation profiling achieved a sensitivity of 50.8% and a specificity of 95.3% in the training cohort, providing an inferior diagnostic performance compared to the methylation assay. Further analyses were performed in an independent validation cohort, including HCC patients (n=112) as well as healthy control (n=96). The cfDNA methylation model achieved a sensitivity of 82.9%, and a specificity of 93.8%; all stage sensitivity excluding BCLC stage 0 was 92.8%. On the other hand, the diagnostic model based on mutation profile achieved a sensitivity of 43.8% and a specificity of 97.9% in this cohort. Furthermore, we found that the methylation model had a sensitivity of 76.6% for early HCC (BCLC stage 0 + A), while serum AFP level (>20ng/ml) had a sensitivity of 27.3%. In conclusion, our results suggest that cancer-derived abnormal methylation pattern of cfDNA provides promising biomarkers for the diagnosis of HCC with high sensitivity and specificity. Citation Format: Yuying Wang, Yupeng Wang, Ao Huang, Ruijingfang Jiang, Jianchao Zheng, Zhilong Li, Jiaxi Peng, Jianlong Sun, Chichuan Liu, Guanghui Yang, Jie Yuan, Xinrong Yang, Jian Zhou, Jia Fan. The genetic and epigenetic abnormalities of plasma cfDNA as liquid biopsy biomarkers to diagnose hepatocellular carcinoma [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 782.

Monitoring hepatocellular carcinoma using tumor content in circulating cell-free DNA

Longitudinal and Personalized Detection of Circulating Tumor DNA (ctdna) for Monitoring Efficacy of Atezolizumab Plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma (HCC).

Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma

Dynamical Detection and Characterization of Circulating Tumor DNA in Patients with Hepatocellular Carcinoma

Data from Circulating Tumor Cells with Stem-Like Phenotypes for Diagnosis, Prognosis, and Therapeutic Response Evaluation in Hepatocellular Carcinoma

Early detection of hepatocellular carcinoma using cfDNA signatures from cirrhotic patients with nodules.

Genome-Scale Profiling of Circulating Cell-Free DNA Signatures for Early Detection of Hepatocellular Carcinoma in Patients with Cirrhosis

Abstract 782: the Genetic and Epigenetic Abnormalities of Plasma Cfdna As Liquid Biopsy Biomarkers to Diagnose Hepatocellular Carcinoma

Cell-free DNA testing for early hepatocellular carcinoma surveillance

Noninvasive Detection of Hepatocellular Carcinoma with Circulating Tumor DNA Features and Α-Fetoprotein

The Diagnostic and Prognostic Usage of Circulating Tumor DNA in Operable Hepatocellular Carcinoma.

5-Hydroxymethylcytosines from Circulating Cell-free DNA As Diagnostic and Prognostic Markers for Hepatocellular Carcinoma

Clinical Application Value of Circulating Cell-free DNA in Hepatocellular Carcinoma

Circulating Tumour Cell Combined with DNA Methylation for Early Detection of Hepatocellular Carcinoma

Liquid Biopsy by Combining 5-Hydroxymethylcytosine Signatures of Plasma Cell-Free DNA and Protein Biomarkers for Diagnosis and Prognosis of Hepatocellular Carcinoma

Circulating Tumor DNA As a Potential Indicator of Tumor Load During Interventional Therapy of Unresectable Hepatocellular Carcinoma.

Serial Circulating Tumor DNA to Predict Early Recurrence in Patients with Hepatocellular Carcinoma: a Prospective Study.

Genome-wide Mapping of 5-Hydroxymethylcytosines in Circulating Cell-Free DNA As a Non-Invasive Approach for Early Detection of Hepatocellular Carcinoma

Circulating Tumor DNA As an Emerging Liquid Biopsy Biomarker for Early Diagnosis and Therapeutic Monitoring in Hepatocellular Carcinoma

Genome-wide methylation profiling of the different stages of hepatitis B virus-related hepatocellular carcinoma development in plasma cell-free DNA reveals potential biomarkers for early detection and high-risk monitoring of hepatocellular carcinoma

Detection of Tumor-Related Biomarkers in Hepatocellular Carcinoma Patients by Sequencing Circulating Cell-Free DNA